annual EBITDA:
-$2.88M+$64.57M(+95.74%)Summary
- As of today (September 13, 2025), SPRY annual EBITDA is -$2.88 million, with the most recent change of +$64.57 million (+95.74%) on December 31, 2024.
- During the last 3 years, SPRY annual EBITDA has risen by +$16.37 million (+85.06%).
- SPRY annual EBITDA is now at all-time high.
Performance
SPRY EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly EBITDA:
-$47.34M-$10.44M(-28.29%)Summary
- As of today (September 13, 2025), SPRY quarterly EBITDA is -$47.34 million, with the most recent change of -$10.44 million (-28.29%) on June 30, 2025.
- Over the past year, SPRY quarterly EBITDA has dropped by -$32.01 million (-208.93%).
- SPRY quarterly EBITDA is now -199.96% below its all-time high of $47.35 million, reached on December 31, 2024.
Performance
SPRY quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM EBITDA:
-$58.60M-$32.01M(-120.39%)Summary
- As of today (September 13, 2025), SPRY TTM EBITDA is -$58.60 million, with the most recent change of -$32.01 million (-120.39%) on June 30, 2025.
- Over the past year, SPRY TTM EBITDA has dropped by -$1.93 million (-3.41%).
- SPRY TTM EBITDA is now -1938.40% below its all-time high of -$2.88 million, reached on December 31, 2024.
Performance
SPRY TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
SPRY EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +95.7% | -208.9% | -3.4% |
| 3 y3 years | +85.1% | -641.8% | +0.1% |
| 5 y5 years | +87.2% | -681.1% | -236.1% |
SPRY EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +95.7% | -200.0% | at low | -1938.4% | +13.1% |
| 5 y | 5-year | at high | +95.7% | -200.0% | at low | -1938.4% | +33.1% |
| alltime | all time | at high | +95.7% | -200.0% | at low | -1938.4% | +33.1% |
SPRY EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2025 | - | -$47.34M(+28.3%) | -$58.60M(+120.4%) |
| Mar 2025 | - | -$36.90M(-177.9%) | -$26.59M(+824.9%) |
| Dec 2024 | -$2.88M(-95.7%) | $47.35M(-318.0%) | -$2.88M(-95.2%) |
| Sep 2024 | - | -$21.73M(+41.8%) | -$60.44M(+6.7%) |
| Jun 2024 | - | -$15.32M(+16.2%) | -$56.67M(-8.5%) |
| Mar 2024 | - | -$13.18M(+29.0%) | -$61.94M(-8.2%) |
| Dec 2023 | -$67.45M(+91.6%) | -$10.21M(-43.1%) | -$67.45M(+17.8%) |
| Sep 2023 | - | -$17.96M(-12.8%) | -$57.23M(+24.7%) |
| Jun 2023 | - | -$20.58M(+10.1%) | -$45.90M(+44.8%) |
| Mar 2023 | - | -$18.69M(+182.2%) | -$31.70M(-26.5%) |
| Dec 2022 | -$35.20M | - | - |
| Sep 2022 | - | -$6.62M(+3.8%) | -$43.13M(-26.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2022 | - | -$6.38M(-9.5%) | -$58.65M(-23.1%) |
| Mar 2022 | - | -$7.05M(-69.5%) | -$76.28M(-13.0%) |
| Dec 2021 | -$19.24M(-38.3%) | - | - |
| Dec 2021 | - | -$23.08M(+4.2%) | -$87.66M(+13.5%) |
| Sep 2021 | - | -$22.14M(-7.8%) | -$77.21M(+40.2%) |
| Jun 2021 | - | -$24.02M(+30.4%) | -$55.07M(+48.4%) |
| Mar 2021 | - | -$18.42M(+45.8%) | -$37.12M(+57.7%) |
| Dec 2020 | -$31.21M(+38.6%) | -$12.64M(+108.5%) | -$23.54M(+35.0%) |
| Jun 2020 | - | -$6.06M(+25.2%) | -$17.44M(+53.3%) |
| Mar 2020 | - | -$4.84M(-25.9%) | -$11.38M(+74.1%) |
| Dec 2019 | -$22.52M(+33.3%) | -$6.54M | -$6.54M |
| Dec 2018 | -$16.90M | - | - |
FAQ
- What is ARS Pharmaceuticals, Inc. annual EBITDA?
- What is the all time high annual EBITDA for ARS Pharmaceuticals, Inc.?
- What is ARS Pharmaceuticals, Inc. annual EBITDA year-on-year change?
- What is ARS Pharmaceuticals, Inc. quarterly EBITDA?
- What is the all time high quarterly EBITDA for ARS Pharmaceuticals, Inc.?
- What is ARS Pharmaceuticals, Inc. quarterly EBITDA year-on-year change?
- What is ARS Pharmaceuticals, Inc. TTM EBITDA?
- What is the all time high TTM EBITDA for ARS Pharmaceuticals, Inc.?
- What is ARS Pharmaceuticals, Inc. TTM EBITDA year-on-year change?
What is ARS Pharmaceuticals, Inc. annual EBITDA?
The current annual EBITDA of SPRY is -$2.88M
What is the all time high annual EBITDA for ARS Pharmaceuticals, Inc.?
ARS Pharmaceuticals, Inc. all-time high annual EBITDA is -$2.88M
What is ARS Pharmaceuticals, Inc. annual EBITDA year-on-year change?
Over the past year, SPRY annual EBITDA has changed by +$64.57M (+95.74%)
What is ARS Pharmaceuticals, Inc. quarterly EBITDA?
The current quarterly EBITDA of SPRY is -$47.34M
What is the all time high quarterly EBITDA for ARS Pharmaceuticals, Inc.?
ARS Pharmaceuticals, Inc. all-time high quarterly EBITDA is $47.35M
What is ARS Pharmaceuticals, Inc. quarterly EBITDA year-on-year change?
Over the past year, SPRY quarterly EBITDA has changed by -$32.01M (-208.93%)
What is ARS Pharmaceuticals, Inc. TTM EBITDA?
The current TTM EBITDA of SPRY is -$58.60M
What is the all time high TTM EBITDA for ARS Pharmaceuticals, Inc.?
ARS Pharmaceuticals, Inc. all-time high TTM EBITDA is -$2.88M
What is ARS Pharmaceuticals, Inc. TTM EBITDA year-on-year change?
Over the past year, SPRY TTM EBITDA has changed by -$1.93M (-3.41%)